# Inventiva (IVA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IVA
## Company Profile
- Ticker: IVA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: France and listed in the U
## Stock Data
- Close: 4.67 USD
- Market cap: 854597009.16 USD
- Last updated: 2026-09-08
## Business Overview
Inventiva is a biotechnology company focused on liver disease and fibrotic conditions, especially metabolic and inflammatory pathways. Its story is centered on MASH and related liver biology.
## Why The Stock Is Moving

The latest monitored company update is “Inventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026.” The corresponding closing-price reaction is not yet available.

## Geographic Base

Headquartered in France and listed in the U.S. as an ADR, Inventiva has a global specialty-biopharma profile.

## Business Model

The company depends on clinical data, dose selection, and the possibility of building a durable liver-disease franchise.

## Landscape Position

Inventiva is a catalyst-sensitive liver-disease name whose stock reacts strongly to clinical progress.

## Future Catalysts

- Inventiva’s catalyst is lanifibranor, especially the MASH / liver-disease development path and any follow-up that keeps the program on track. The market will watch whether the asset can continue to support a credible metabolic-liver story.

## Recent News
- 2026-09-08 20:00 EST — [Inventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026](https://biopharmsignal.com/news/IVA/inventiva-pr-sentera-plusieurs-abstracts-lors-du-congr-s-paris-mash-2026-33e2577b) — Source: Inventiva
- 2026-09-08 20:00 EST — [Inventiva to Present Multiple Abstracts at Paris MASH 2026](https://biopharmsignal.com/news/IVA/inventiva-to-present-multiple-abstracts-at-paris-mash-2026-64e9b596) — Source: Inventiva
- 2026-09-02 20:05 EST — [Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH](https://biopharmsignal.com/news/IVA/inventiva-annonce-la-derni-re-visite-du-dernier-patient-de-l-tude-clinique-de-ph-9870f053) — Source: Inventiva
- 2026-09-02 20:05 EST — [Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH](https://biopharmsignal.com/news/IVA/inventiva-announces-last-patient-visit-in-nativ3-phase-3-clinical-trial-of-lanif-1e5d546a) — Source: Inventiva
- 2026-08-31 20:05 EST — [Inventiva nomme Chris Benecchi au poste de Chief Operating Officer](https://biopharmsignal.com/news/IVA/inventiva-nomme-chris-benecchi-au-poste-de-chief-operating-officer-efc9ca7f) — Source: Inventiva